Kearns & Associates’s Schwab Emerging Markets Equity ETF SCHE Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$966K Buy
26,649
+501
+2% +$17.9K 0.45% 21
2026
Q1
$862K Buy
26,148
+300
+1% +$10.2K 0.46% 19
2025
Q4
$847K Buy
25,848
+610
+2% +$20.3K 0.44% 22
2025
Q3
$842K Sell
25,238
-1
-0% -$32 0.45% 21
2025
Q2
$761K Hold
25,239
0.44% 21
2025
Q1
$696K Hold
25,239
0.45% 22
2024
Q4
$672K Hold
25,239
0.43% 20
2024
Q3
$736K Hold
25,239
0.49% 19
2024
Q2
$670K Buy
25,239
+589
+2% +$15.4K 0.5% 18
2024
Q1
$622K Buy
24,650
+1,794
+8% +$44.1K 0.48% 21
2023
Q4
$567K Hold
22,856
0.48% 20
2023
Q3
$547K Hold
22,856
0.52% 17
2023
Q2
$563K Hold
22,856
0.51% 17
2023
Q1
$560K Hold
22,856
0.56% 14
2022
Q4
$541K Hold
22,856
0.57% 16
2022
Q3
$512K Hold
22,856
0.69% 9
2022
Q2
$580K Hold
22,856
0.77% 9
2022
Q1
$635K Hold
22,856
0.66% 10
2021
Q4
$677K Buy
+22,856
New +$698K 0.66% 10

Other funds holding SCHE

Kearns & Associates's SCHE Position: Q2 2026 in Review

Kearns & Associates increased its Schwab Emerging Markets Equity ETF (SCHE) stake by 1.9% in Q2 2026, buying an estimated $17.9K and bringing the position to 26,649 shares worth $966K. The position accounts for 0.45% of the portfolio, ranked #21.

Kearns & Associates first reported a position in SCHE in Q4 2021 and has held it in 19 quarters since. 424 funds tracked by Wall St. Rank hold SCHE as of Q2 2026.

  • Kearns & Associates held 26,649 shares of Schwab Emerging Markets Equity ETF worth $966K as of Q2 2026.
  • Kearns & Associates bought 501 Schwab Emerging Markets Equity ETF shares in Q2 2026, an estimated $17.9K.
  • Schwab Emerging Markets Equity ETF made up 0.45% of Kearns & Associates's portfolio in Q2 2026, its #21 holding.
  • Kearns & Associates first reported a position in Schwab Emerging Markets Equity ETF in Q4 2021 and has held it in 19 quarters since.
  • 424 funds tracked by Wall St. Rank held Schwab Emerging Markets Equity ETF as of Q2 2026.

Based on Kearns & Associates's 13F filing for Q2 2026, filed 23 Jul 2026.